A Phase 3, Multicenter, Double-Masked, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-Related Macular Degeneration
Clinical Trial Grant
Administered By
Ophthalmology, Vitreoretinal Diseases & Surgery
Awarded By
Ocular Therapeutix Inc
Start Date
August 1, 2024
End Date
August 14, 2029
Administered By
Ophthalmology, Vitreoretinal Diseases & Surgery
Awarded By
Ocular Therapeutix Inc
Start Date
August 1, 2024
End Date
August 14, 2029